Drugs / KXV01 TCR Lentinvivo Injection
last change Dec 2025 re-read 3 minutes ago

KXV01 TCR Lentinvivo Injection

Developed for
cancer
Investigated by
Shanghai Jiao Tong University Affiliated Sixth People's Hospital · TCRx Therapeutics Co.Ltd

Trials 1

202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07596693 Dec 2025 → Dec 2027 expected cancer TCRx Therapeutics Co.Ltd Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as KXV01 TCR Lentinvivo Injection ClinicalTrials.gov intervention name — accepted as the source's own label NCT07596693 ↗